Clinical Trial Update: Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial of exatecan mesylate for Ewing's sarcoma, primitive neuroectodermal tumor, and desmoplastic small round cell tumor has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoplastic Small Round Cell Tumor
• Ewing Sarcoma
• Primitive Neuroectodermal Tumor

Drugs mentioned

• Exatecan Mesylate (exatecan mesylate)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Sarcoma | Phase 2 | Status: COMPLETED